SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000891293-21-000041
Filing Date
2021-08-05
Accepted
2021-08-05 17:02:25
Documents
38
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ctic-20210630.htm   iXBRL 10-Q 833802
2 EX-31.1 ex311-ceo302q2fy21.htm EX-31.1 11336
3 EX-31.2 ex312-cfo302q2fy21.htm EX-31.2 12204
4 EX-32 ex32-ceocfo906q2fy21.htm EX-32 11649
  Complete submission text file 0000891293-21-000041.txt   3343350

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20210630.xsd EX-101.SCH 20133
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ctic-20210630_cal.xml EX-101.CAL 47401
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ctic-20210630_def.xml EX-101.DEF 123911
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20210630_lab.xml EX-101.LAB 296888
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20210630_pre.xml EX-101.PRE 180848
10 EXTRACTED XBRL INSTANCE DOCUMENT ctic-20210630_htm.xml XML 422854
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-28386 | Film No.: 211149291
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences